sign in sign up
<<
Home , Adrenorphin, Asimadoline, Deltorphin, Difelikefalin, Dynorphin A, Exorphin

Opioid Receptor

Opioid receptors are a group of G protein-coupled receptors with as ligands. The endogenous opioids are , , , and . Opioid receptors are distributed widely in the brain, and are found in the spinal cord and digestive tract. Opioid receptors are molecules, or sites, within the body that are activated by opioid substances. Opioid receptors inhibit the transmission of impulse in excitatory pathways within the body system. These pathways include the serotonin, catecholamine, and pathways, which are all implicated in perception and feelings of well-being. Opioid receptors are further subclassified into mu, delta, and kappa receptors. All the classes, while exhibiting differing modes of action, share some basic similarities. They all are driven by the potassium pump mechanism, which is found on the plasma membrane of the majority of cells.

www.MedChemExpress.com 1 , Antagonists, Inhibitors, Activators & Modulators

6'-GNTI dihydrochloride 6-Alpha Cat. No.: HY-110302 (Alpha-Naloxol) Cat. No.: HY-12799

6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) 6-Alpha Naloxol(Alpha-Naloxol) is an opioid , displays bias toward the activation of G antagonist closely related to ; a human protein-mediated signaling over β-arrestin2 metabolite of naloxone. recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

6-beta-Naloxol D5 hydrochloride Ac-RYYRIK-NH2 (6β-Naloxol D5 hydrochloride) Cat. No.: HY-12780S Cat. No.: HY-P1318

6-beta-Naloxol D5 hydrochloride is the deuterium Ac-RYYRIK-NH2 is a potent and partial agonist on

labeled 6-beta-Naloxol, which is an opioid ORL1 transfected in CHO cells (Kd=1.5 nM) and antagonist closely related to naloxone. behaves as a endogenous ligand of ORL1.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Ac-RYYRIK-NH2 TFA Ac-RYYRWK-NH2 Cat. No.: HY-P1318A Cat. No.: HY-P1316

Ac-RYYRIK-NH2 TFA is a potent and partial agonist Ac-RYYRWK-NH2 is a potent and selective partial

on ORL1 transfected in CHO cells (Kd=1.5 nM) agonist for the (NOP), and behaves as a endogenous ligand of ORL1. [3H]Ac-RYYRWK-NH2 binds to rat cortical

membranes ORL1 with a Kd of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Ac-RYYRWK-NH2 TFA ADL-5859 Cat. No.: HY-P1316A Cat. No.: HY-13044

Ac-RYYRWK-NH2 is a potent and selective partial ADL5859 is a δ-opioid receptor agonist with Ki of agonist for the nociceptin receptor (NOP), 0.8 nM, selectivity against opioid receptor κ, μ, [3H]Ac-RYYRWK-NH2 binds to rat cortical and weak inhibitory activity at the hERG channel.

membranes ORL1 with a Kd of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors.

Purity: >98% Purity: 99.77% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Adrenorphin Akuammidine (Metorphamide) Cat. No.: HY-P1087 Cat. No.: HY-N7437

Adrenorphin is a opioid octapeptide, acting as a Akuammidine, isolated from the seeds of

potent agonist of μ-opioid receptor, with Ki of 12 Picralima nitida, shows a preference for μ-opioid

nM. binding sites with Ki values of 0.6, 2.4 and 8.6 μM at μ-, σ- and κ-opioid binding sites, respectively. Akuammidine possesses anti-inflammatory and anti-asthmatic properties. Purity: 95.49% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Alvimopan dihydrate (ADL 8-2698; LY 246736) Cat. No.: HY-13243 (ADL 8-2698 dihydrate; LY 246736 dihydrate) Cat. No.: HY-76657A

Alvimopan (ADL 8-2698) is a potent, selective, Alvimopan dihydrate (ADL 8-2698 dihydrate) is a orally active and reversible μ-opioid receptor potent, selective, orally active and reversible antagonist, with an IC50 of 1.7 nM. Alvimopan has μ-opioid , with an IC50 of 1.7 selectivity for μ-opioid receptor (Ki=0.47 nM) nM. over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Purity: >98% Purity: 98.70% Clinical Data: Launched Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Alvimopan monohydrate AR-M 1000390 hydrochloride (ADL 8-2698 monohydrate; LY 246736 monohydrate) Cat. No.: HY-76657 Cat. No.: HY-101039A

Alvimopan monohydrate (ADL 8-2698 monohydrate) is AR-M 1000390 hydrochloride is an exceptionally a potent, selective, orally active and reversible selective, potent δ opioid receptor agonist with

μ-opioid receptor antagonist, with an IC50 of 1.7 an EC50 of 7.2±0.9 nM for δ agonist . nM.

Purity: 99.18% Purity: 99.80% Clinical Data: Launched Clinical Data: No Development Reported Size: 2 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Asimadoline hydrochloride (EMD-61753) Cat. No.: HY-107384 (EMD-61753 hydrochloride) Cat. No.: HY-107384A

Asimadoline (EMD-61753) is an orally active, Asimadoline (EMD-61753) hydrochloride is an orally selective and peripherally active κ-opioid agonist active, selective and peripherally active κ-opioid with IC50s of 5.6 nM (guinea pig) and 1.2 nM agonist with IC50s of 5.6 nM (guinea pig) and 1.2 (human recombinant). nM (human recombinant).

Purity: 99.36% Purity: 99.80% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AT-121 AT-121 hydrochloride Cat. No.: HY-112692 Cat. No.: HY-112692A

AT-121 is a bifunctional nociception and mu AT-121 hydrochloride is a bifunctional nociception opioid receptor agonist, with Kis of 3.67 and and mu opioid receptor agonist, with Kis of 16.49 nM, respectively. AT-121 is a safe, 3.67 and 16.49 nM, respectively. AT-121 non-addictive , and shows antinociceptive hydrochloride is a safe, non-addictive analgesic, and antiallodynic effects. and shows antinociceptive and antiallodynic effects. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Aticaprant BAM-22P (CERC-501; LY-2456302) Cat. No.: HY-101718 (Bovine adrenal medulla-22P) Cat. No.: HY-P1331

Aticaprant (CERC-501) is a potent and BAM-22P, a highly potent opioid , is a centrally-penetrant kappa opioid receptor potent opioid agonist. antagonist with a Ki of 0.807 nM.

Purity: 99.86% Purity: >98% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg, 50 mg Size: 500 μg, 1 mg, 5 mg

www.MedChemExpress.com 3

BAN ORL 24 Cat. No.: HY-13222 (CB-5945; ADL-5945) Cat. No.: HY-100122

BAN ORL 24 is a potent and selective NOP receptor Bevenopran is a peripheral μ-opioid receptor antagonist. (IC50 values are 0.27, 2500, 6700 and antagonist. > 10000 nM for NOP, κ-, μ- and δ-receptors respectively).

Purity: 98.09% Purity: >98% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

BPR1M97 BTRX-335140 Cat. No.: HY-128865 (CYM-53093) Cat. No.: HY-124754

BPR1M97 is a dual-acting mu opioid receptor BTRX-335140 (CYM-53093) is a potent and selective, (MOP) and nociceptin-orphanin FQ peptide (NOP) orally active κ opioid receptor (KOR)

receptor agonist with Ki values of 1.8 and 4.2 antagonist, has antagonist activity for κOR, μOR

nM, respectively. BPR1M97 shows high potency and and δOR with IC50 values of 0.8 nM, 110 nM, and blood-brain barrier penetration, and produces 6500 nM, respectively. potent antinociceptive effects. Purity: 98.99% Purity: 99.71% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cebranopadol ((1α,4α)stereoisomer) (GRT6005) Cat. No.: HY-15536 (GRT6005 (1α,4α)stereoisomer) Cat. No.: HY-15536A

Cebranopadol is an analgesic NOP and opioid Cebranopadol ((1α,4α)stereoisomer) is a

receptor agonist with Kis/EC50s of 0.9 nM/13 stereoisomer of cebranopadol. Cebranopadol is a nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for potent agonist activity on ORL-1. human NOP, MOP, KOP and delta- (DOP) receptor, respectively.

Purity: 96.91% Purity: 95.60% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 2 mg, 5 mg

Corydaline CTAP ((+)-Corydaline; Corydalin) Cat. No.: HY-N0923 Cat. No.: HY-P1335

Corydaline ((+)-Corydaline), an isoquinoline CTAP is a potent, highly selective, and brain

alkaloid isolated from Corydalis yanhusuo, is an penetrant μ opioid receptor antagonist (IC50=3.5

AChE inhibitor with an IC50 of 226 µM. Corydaline nM) and displays over 1200-fold selectivity over δ

is a μ-opioid receptor (Ki of 1.23 µM) agonist and opioid (IC50=4500 nM) and receptors.

inhibits enterovirus 71 (EV71) replication (IC50 CTAP can be used for the study of L-DOPA-induced of 25.23 µM). dyskinesia (LID). Purity: 96.17% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 1 mg, 5 mg

CTAP TFA CTOP Cat. No.: HY-P1335A Cat. No.: HY-P1329

CTAP TFA is a potent, highly selective, and brain CTOP is a peptide that acts as a μ-opioid receptor

penetrant μ opioid receptor antagonist (IC50=3.5 antagonist. nM) and displays over 1200-fold selectivity over δ

opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID). Purity: 99.48% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg

4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

CTOP TFA DAMGO Cat. No.: HY-P1329A Cat. No.: HY-P0210

CTOP TFA is a peptide that acts as a μ-opioid DAMGO is a μ-opioid receptor (μ-OPR ) selective receptor antagonist. agonist with a Kd of 3.46 nM for native μ-OPR.

Purity: 99.93% Purity: 99.13% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

DAMGO (TFA) 2 Cat. No.: HY-P0210B ([D-Ala2]-Deltorphin II) Cat. No.: HY-P1013

DAMGO TFA is a μ-opioid receptor (μ-OPR ) Deltorphin 2 is a selective peptide agonist for selective agonist with a Kd of 3.46 nM for the δ opioid receptor. native μ-OPR.

Purity: 99.32% Purity: >98% Clinical Data: Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg, 10 mg, 25 mg

Deltorphin 2 TFA ([D-Ala2]-Deltorphin II TFA) Cat. No.: HY-P1013A (Deltorphin 1; Deltorphin C) Cat. No.: HY-P1336

Deltorphin 2 TFA is a selective peptide agonist Deltorphin I is a δ-opioid receptor agonist with for the δ opioid receptor. high affinity and selectivity.

Purity: 98.11% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg, 5 mg

Dermorphin Analog Cat. No.: HY-P0244 Cat. No.: HY-P1577

Dermorphin is a natural heptapeptide μ-opioid Dermorphin Analog is an analog of Dermorphin. receptor (MOR) agonist found in amphibian Dermorphin is a natural heptapeptide μ-opioid skin. Inhibition of neuropathic pain. receptor agonist found in amphibian skin.

Purity: 99.64% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg, 10 mg

Dermorphin TFA Cat. No.: HY-P0244A (CR-845; FE-202845) Cat. No.: HY-17609

Dermorphin TFA is a natural heptapeptide μ-opioid Difelikefalin (CR-845; FE-202845) is a receptor (MOR) agonist found in amphibian peripherally restricted and selective agonist of skin. Inhibition of neuropathic pain. kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease. Purity: >98% Purity: 99.30% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg

www.MedChemExpress.com 5

DPDPE DPDPE TFA Cat. No.: HY-P1334 Cat. No.: HY-P1334A

DPDPE, an opioid peptide, is a selective δ-opioid DPDPE TFA, an opioid peptide, is a selective receptor (DOR) agonist with δ-opioid receptor (DOR) agonist with anticonvulsant effects. anticonvulsant effects.

Purity: 98.22% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

DPI-3290 A (Org 41793) Cat. No.: HY-19231 Cat. No.: HY-P1333

DPI-3290 (Org 41793) is a potent and specific , an endogenous opioid peptide, is a

opioid receptors agonist with Ki values of 0.18 highy potent kappa opioid receptor (KOR) nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid activator. Dynorphin A also serve as an agonist receptors, respectivelyDPI-3290 is one of a for other opioid receptors, such as mu (MOR) series of novel centrally acting agents with and delta (DOR). potent antinociceptive activity. Purity: >98% Purity: 98.59% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg, 10 mg

Dynorphin A (1-10) (TFA) Dynorphin A (1-8) Cat. No.: HY-P1594A Cat. No.: HY-P2159

Dynorphin A (1-10) (TFA), an endogenous opioid Dynorphin A (1-8) is the predominant opioid , binds to extracellular loop 2 of the peptide identified in placental tissue extracts. κ-opioid receptor. Dynorphin A (1-10) (TFA) also Dynorphin A (1-8) is the most likely natural

blocks NMDA-activated current with an IC50 of ligand of the kappa receptor. The binding of 42.0 μM. 3H- to the purified kappa receptor is

inhibited by Dynorphin A (1-8) (IC50=303 nM). Purity: 95.04% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg

Dynorphin A 1-10 Dynorphin A TFA Cat. No.: HY-P1594 Cat. No.: HY-P1333A

Dynorphin A (1-10) an endogenous opioid Dynorphin A TFA, an endogenous opioid peptide, is neuropeptide, binds to extracellular loop 2 of the a highy potent kappa opioid receptor (KOR) κ-opioid receptor. Dynorphin A (1-10) also blocks activator. Dynorphin A TFA also serve as an

NMDA-activated current with an IC50 of 42.0 μM. agonist for other opioid receptors, such as mu (MOR) and delta (DOR).

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Dynorphin B (1-13) (1-13) (TFA) Cat. No.: HY-P1337 Cat. No.: HY-P1337A

Dynorphin B (1-13) acts as an agonist on opioid Dynorphin B (1-13) TFA acts as an agonist on opioid κ-receptor. κ-receptor.

Purity: >98% Purity: 98.98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg, 10 mg

6 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Endomorphin 1 2 Cat. No.: HY-P0185 Cat. No.: HY-P0186

Endomorphin 1, a high affinity, highly selective Endomorphin 2, a high affinity, highly selective agonist of the μ-opioid receptor, displays agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. with Ki value between 20 and 30 nM.

Purity: 95.10% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

Endomorphin 2 TFA EST73502 Cat. No.: HY-P0186A Cat. No.: HY-134189

Endomorphin 2 TFA, a high affinity, highly EST73502 is a selective, orally active and selective agonist of the μ-opioid receptor, blood-brain barrier (BBB) penetrant dual μ-opioid displays reasonable affinities for kappa3 binding receptor (MOR) agonist and σ1 receptor (σ1R) sites, with Ki value between 20 and 30 nM. antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity. Purity: 99.94% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

EST73502 hydrochloride Cat. No.: HY-134189A Cat. No.: HY-106147

EST73502 hydrochloride is a selective, orally Frakefamide is a potent analgesic that acts as a active and blood-brain barrier (BBB) penetrant peripheral active μ-selective receptor agonist. dual μ-opioid receptor (MOR) agonist and σ1 Frakefamide is unable to penetrate the receptor (σ1R) antagonist, with Kis of 64 nM and blood-brain-barrier and enter the central nervous 118 nM for MOR and σ1R, respectively. EST73502 system. hydrochloride has antinociceptive activity. Purity: 98.12% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

Frakefamide TFA Gluten B5 Cat. No.: HY-106147B Cat. No.: HY-P1742

Frakefamide TFA is a potent analgesic that acts as Gluten Exorphin B5 is an exogenous opioid a peripheral active μ-selective receptor agonist. derived from wheat gluten, acts on opioid Frakefamide is unable to penetrate the receptor, increases postprandial plasma insulin blood-brain-barrier and enter the central nervous level in rats. system.

Purity: 99.18% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

Gluten Exorphin C GSK1521498 Cat. No.: HY-P1596 Cat. No.: HY-19902

Gluten exorphin C is an opioid peptide derived GSK1521498 is a potent and selective μ-opioid from wheat gluten. Its IC50 values are 40 μM and receptor (MOR) antagonist. GSK1521498 has the 13.5 μM for μ opioid and δ opioid activities in potential for disorders of compulsive consumption the GPI and MVD assays, respectively. of food, , and drugs.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 7

GSK1521498 free base GSK1521498 free base (hydrochloride) Cat. No.: HY-115066 Cat. No.: HY-115066A

GSK1521498 free base is a potent and selective GSK1521498 free base (hydrochloride) is a potent μ-opioid receptor (MOR) antagonist. GSK1521498 and selective μ-opioid receptor (MOR) free base has the potential for disorders of antagonist. GSK1521498 free base (hydrochloride) compulsive consumption of food, alcohol, and is being used for the treatment of disorders of drugs. compulsive consumption of food, alcohol, and drugs. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Hecogenin -7 Cat. No.: HY-126941 Cat. No.: HY-P0318

Hecogenin acetate is a steroidal Hemorphin-7 is a hemorphin peptide, an endogenous sapogenin-acetylated with anti-inflammatory and opioid peptide derived from the β-chain of antinociceptive. Hecogenin acetate shows potential hemoglobin. Hemorphin peptides exhibits antihyperalgesic activity, inhibiting descending antinociceptive and antihypertensive activities, pain and acting in opioid receptors. activating opioid receptors and inhibiting -converting enzyme (ACE). Purity: >98% Purity: 99.65% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 100 mg Size: 1 mg, 5 mg, 10 mg

JDTic JDTic dihydrochloride Cat. No.: HY-10486 Cat. No.: HY-10487

JDTic is a highly selective antagonist for the JDTic (dihydrochloride) is a potent antagonist of κ-opioid receptor; without affecting the μ- or kappa-opioid receptors (KOR), blocking the δ-opioid receptors. κ-agonist U50, 488-induced antinociception.

Purity: >98% Purity: 99.79% Clinical Data: Phase 1 Clinical Data: Phase 1 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JTC-801 Cat. No.: HY-13274 Cat. No.: HY-10827

JTC-801 is a selective opioid receptor-like1 (ORL1) Kelatorphan is a full inhibitor of receptor antagonist, binding to ORL1 receptor degrading enzymes.

with a Ki value of 8.2nM.

Purity: 99.75% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg

Loperamide D6 hydrochloride hydrochloride (R-18553 D6 hydrochloride) Cat. No.: HY-B0418AS (R-18553 hydrochloride) Cat. No.: HY-B0418A

Loperamide D6 hydrochloride (R-18553 D6 Loperamide (hydrochloride) (R-18553 hydrochloride) is a deuterium labeled Loperamide (hydrochloride)) is an opioid receptor agonist. hydrochloride. Loperamide hydrochloride is an Loperamide hydrochloride is a selective and opioid receptor agonist for the treatment of competitive human intestinal carboxylesterases diarrhea. (hiCE) inhibitor. Loperamide hydrochloride has anti-diarrheal effect. Purity: >98% Purity: 99.79% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 100 mg, 500 mg

8 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Loperamide phenyl LY2444296 Cat. No.: HY-136586 (FP3FBZ) Cat. No.: HY-135230

Loperamide phenyl is an impurity of Loperamide LY2444296 is an orally bioavailable, high-affinity (HY-B0418A). Loperamide is an opioid and selective short-acting kappa opioid receptor receptor agonist. (KOPR) antagonist, with a Ki value of 1 nM. LY2444296 exhibits anti- like effects.

Purity: >98% Purity: 99.78% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2795050 LY2940094 Cat. No.: HY-15708 (BTRX-246040) Cat. No.: HY-114452

LY2795050 is a novel selective κ-opioid Receptor LY2940094 (BTRX-246040) is a potent, selective and (KOR) antagonist (IC50=0.72 nM) and has the orally available nociceptin receptor (NOP potential as a PET tracer to image KOR in vivo. receptor) antagonist with high affinity (Ki=0.105

nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models. Purity: 98.12% Purity: 99.56% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY2940094 tartrate (BTRX-246040 tartrate) Cat. No.: HY-114452A (Matridin-15-one; Vegard; α-Matrine) Cat. No.: HY-N0164

LY2940094 (BTRX-246040) tartrate is a potent, Matrine (Matridin-15-one) is an alkaloid found in brain penetrant, selective and orally available plants from the Sophora genus. It has a variety of N/OFQ peptide (NOP) receptor antagonist with high pharmacological effects, including anti-cancer affinity (Ki=0.105 nM) and antagonist potency effects, and action as a kappa opioid receptor and

(Kb=0.166 nM). u-receptor agonist.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

MCOPPB triHydrochloride D3 Bromide (MCOPPB 3HCl) Cat. No.: HY-13101 Cat. No.: HY-75766S

MCOPPB 3Hcl is a nociceptin receptor agonist with Methylnaltrexone D3 Bromide is the deuterium pKi of 10.07; weaker activity at other opioid labeled Methylnaltrexone Bromide. Methylnaltrexone receptors. Bromide is a peripheral-acting opioid receptor antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.

Purity: 99.35% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

MT-7716 free base MT-7716 hydrochloride (W-212393) Cat. No.: HY-107094A (W-212393 hydrochloride) Cat. No.: HY-107094

MT-7716 free base (W-212393) is a selective MT-7716 hydrochloride (W-212393 hydrochloride) is non-peptide nociceptin receptor (NOP) agonist and a selective non-peptide nociceptin receptor (NOP) promising potential treatment drug for alcohol agonist and promising potential treatment drug for abuse and prevention. alcohol abuse and relapse prevention.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 9

N-Desmethylclozapine N-terminally acetylated Leu-enkephalin (Norclozapine; ; Normethylclozapine) Cat. No.: HY-G0021 (Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH) Cat. No.: HY-P1170

N-Desmethylclozapine is a major active metabolite N-terminally acetylated Leu-enkephalin is the of the atypical antipsychotic drug Clozapine. N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

Purity: 99.72% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg, 10 mg, 25 mg

Naldemedine (S-297995) Cat. No.: HY-19627 (TRK-820) Cat. No.: HY-12745

Naldemedine (S-297995) is an orally active, Nalfurafine (TRK-820) is a potent selective and peripherally acting µ-opioid receptor antagonist. orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine (TRK-820) enhances the therapeutic potential of MOR-targeting , has the potential for uremic pruritis treatment. Purity: >98% Purity: >98% Clinical Data: Launched Clinical Data: Launched Size: 5 mg Size: 1 mg, 5 mg

Nalfurafine hydrochloride (TRK-820 hydrochloride) Cat. No.: HY-12745A (NKTR-118; AZ-13337019) Cat. No.: HY-A0118

Nalfurafine hydrochloride (TRK-820 hydrochloride) Naloxegol (NKTR-118; AZ-13337019) is a is a potent selective and orally active G μ-opioid-receptor antagonist. Naloxegol inhibits protein-biased kappa opioid receptor (KOR)-agonist opioid binding in μ-opioid receptors in the with high translational potential. gastrointestinal tract and effective for alleviating opioid-induced constipation.

Purity: 99.93% Purity: >98% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg

Naloxegol oxalate hydrochloride (NKTR-118 oxalate; AZ-13337019 oxalate) Cat. No.: HY-A0118A Cat. No.: HY-101177

Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 Naltrindole hydrochloride is a highly potent and oxalate) is a μ-opioid-receptor antagonist. selective non-peptide δ opioid receptor antagonist

Naloxegol oxalate inhibits opioid binding in with a Ki of 0.02 nM. μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation. Purity: 99.90% Purity: 95.05% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Neuropeptide AF (human) Nociceptin (Neuropeptide AF (93-110), human) Cat. No.: HY-P1246 (Orphanin FQ) Cat. No.: HY-P0183

Neuropeptide AF (human) is an endogenous Nociceptin, a heptadecapeptide, is the endogenous antiopioid peptide. ligand of the nociceptin receptor, acting as a potent anti-analgesic.

Purity: >98% Purity: 99.83% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 500 μg, 1 mg, 5 mg Size: 1 mg, 5 mg, 10 mg, 25 mg

10 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Nociceptin (1-13), amide Nociceptin(1-7) Cat. No.: HY-P1317 Cat. No.: HY-P1319

Nociceptin (1-13), amide is a potent ORL1 (OP4) Nociceptin (1-7) is the N-terminal bioactive receptor agonist with a pEC50 of 7.9 for mouse fragment of nociceptin (HY-P0183). Nociceptin vas deferens and a Ki of 0.75 nM for binding to (1-7) is a potent ORL1 (NOP) receptor rat forebrain membranes. agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Nociceptin(1-7) TFA dihydrochloride (nor- Cat. No.: HY-P1319A dihydrochloride; nor-BNI dihydrochloride) Cat. No.: HY-100903

Nociceptin (1-7) TFA is the N-terminal bioactive Norbinaltorphimine dihydrochloride is a potent and fragment of nociceptin (HY-P0183). Nociceptin selective κ opioid receptor antagonist.

(1-7) TFA is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo. Purity: >98% Purity: 98.60% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg

Noscapine Noscapine hydrochloride ((S,R)-Noscapine) Cat. No.: HY-13716 ((S,R)-Noscapine hydrochloride) Cat. No.: HY-13716A

Noscapine ((S,R)-Noscapine) is an orally active Noscapine hydrochloride ((S,R)-Noscapine phthalideisoquinoline alkaloid with potent hydrochloride) is an orally active antitussive. Noscapine exerts its antitussive phthalideisoquinoline alkaloid with potent effects by activating sigma opioid receptors antitussive. and is a non-competitive inhibitor.

Purity: 98.19% Purity: 99.99% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 100 mg

Opioid 1 ORL1 antagonist 1 Cat. No.: HY-U00420 Cat. No.: HY-112263

Opioid receptor modulator 1 is a opioid receptor ORL1 antagonist 1 is an opioid receptor-like 1 modulator extracted from patent WO2014072809A2, (ORL1) antagonist with an IC50 of 61 nM. Compound RA11 in EXAMPLE 7.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Orphanin FQ(1-11) Orphanin FQ(1-11) TFA Cat. No.: HY-P1302 Cat. No.: HY-P1302A

Orphanin FQ(1-11), a orphanin FQ or nociceptin Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (OFQ/N) fragment, is a potent NOP receptor

(ORL-1; OP4) agonist, with a Ki of 55 nM. (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1

κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) is and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) analgesic in CD-1 mice. TFA is analgesic in CD-1 mice. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 11

PL-017 PL-017 TFA Cat. No.: HY-P1338 Cat. No.: HY-P1338A

PL-017 is a potent and selective μ opioid PL-017 TFA is a potent and selective μ opioid

receptor agonist with an IC50 of 5.5 nM for receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces 125I-FK 33,824 binding to μ site. PL-017 TFA long-lasting, reversible analgesia in rats. produces long-lasting, reversible analgesia in rats.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Porcine dynorphin A(1-13) PZM21 (Dynorphin A Porcine Fragment 1-13) Cat. No.: HY-P0088 Cat. No.: HY-101386

Porcine dynorphin A (1-13) is a potent, endogenous PZM21 is a potent and selective μ opioid

κ opioid receptor agonist and is antinociceptive receptor agonist with an EC50 of 1.8 nM. at physiological concentrations.

Purity: 98.99% Purity: 99.84% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ro 64-6198 SB-612111 Cat. No.: HY-12844 Cat. No.: HY-18618

Ro 64-6198 is a potent, selective, nonpeptide, SB-612111 is a novel and potent high-affinity, high cellular permeability and receptor-like orphan receptor (ORL-1) antagonist

brain penetration N/OFQ receptor (NOP) agonist with a high affinity for hORL-1 (Ki=0.33 nM).

with an EC50 value of 25.6 nM. Ro 64-6198 is at SB-612111 exhibits selectivity for μ-, κ-

least 100 times more selective for the NOP and δ-receptors with Ki values of 57.6 receptor over the classic opioid receptors. nM, 160.5 nM and 2109 nM, respecticely. Purity: ≥99.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg Size: 5 mg, 10 mg

SB-612111 hydrochloride Sec-O-Glucosylhamaudol Cat. No.: HY-18617 Cat. No.: HY-N0398

SB-612111 hydrochloride is a novel and potent Sec-O-Glucosylhamaudol is a natural compound human opiate receptor-like orphan receptor extracted from Peucedanum japonicum Thunb, (ORL-1) antagonist with a high affinity for decreases levels of μ-opioid receptor, with

hORL-1 (Ki=0.33 nM). analgesic effect.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 5 mg, 10 mg, 20 mg

Sinomenine hydrochloride Cat. No.: HY-15122 (Cucoline hydrochloride) Cat. No.: HY-15122A

Sinomenine, an alkaloid extracted Sinomenine hydrochloride (Cucoline hydrochloride), from Sinomenium acutum, is a blocker of an alkaloid extracted from Sinomenium the NF-κB activation. Sinomenine also is an acutum, is a blocker of the NF-κB activation. activator of μ-opioid receptor. Sinomenine also is an activator of μ-opioid receptor.

Purity: 98.82% Purity: 99.88% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 100 mg

12 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

SNC80 SR17018 (NIH 10815) Cat. No.: HY-101202 Cat. No.: HY-111454

SNC80 (NIH 10815) is a potent, highly selective SR17018 is an mu-opioid-receptor (MOR) and non-peptide δ-opioid receptor agonist with a agonist, binding with GTPγS, with an EC50 of 97

Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also nM. selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAN-452 Trap-101 hydrochloride Cat. No.: HY-136208 Cat. No.: HY-11052A

TAN-452 is an orally active, selective Trap-101 hydrochloride is a potent, selective and peripherally acting δ-opioid receptor (DOR) competitive antagonist of NOP receptors over antagonist with a Ki of 0.47 nM and a Kb of classical opioid receptors. 0.21 nM.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Trimebutine maleate Cat. No.: HY-B0380 Cat. No.: HY-B0380A

Trimebutine is a drug with antimuscarinic and weak Trimebutine maleate is a drug with antimuscarinic mu opioid agonist effects. Target: Opioid Receptor and weak mu opioid agonist effects. Target: Opioid Trimebutine is an agonist of peripheral mu, kappa Receptor Trimebutine is an agonist of peripheral and delta opiate receptors, used as spasmolytic mu, kappa and delta opiate receptors, used as agent for treatment of both acute and chronic spasmolytic agent for treatment of both acute and abdominal pain . chronic abdominal pain . Purity: >98% Purity: 99.95% Clinical Data: Launched Clinical Data: Launched Size: 500 mg, 5 g Size: 10 mM × 1 mL, 500 mg

Tyr-Gly-Gly-Phe-Met-OH UFP-101 (Met-Enkephalin; Methionine enkephalin) Cat. No.: HY-P0073 Cat. No.: HY-P1299

Tyr-Gly-Gly-Phe-Met-OH regulates human immune UFP-101 is a potent, selective, and competitive function and inhibits tumor growth via binding to antagonist of the NOP receptor, with a pKi of the opioid receptor. 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows -like effect.

Purity: 98.07% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

UFP-101 TFA Cat. No.: HY-P1299A Cat. No.: HY-P1599

UFP-101 TFA is a potent, selective, and Valorphin is an endogenous hemoglobin β-chain competitive antagonist of the N/OFQ peptide (NOP) (33-39) fragment with opioid analgesic activity, receptor, with a pKi of 10.24. UFP-101 TFA binds to rat mu-opioid receptor, with an IC50 displays >3000-fold selectivity over δ, μ and κ of 14 nM; Valorphin also shows anti-tumor opioid receptors. UFP-101 TFA shows activity. antidepressant-like effect. Purity: 99.36% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 13

Vanilpyruvic acid ZT 52656A hydrochloride (Vanylpyruvic acid) Cat. No.: HY-101416 Cat. No.: HY-101582

Vanilpyruvic acid is a catecholamine metabolite ZT 52656A is a selective kappa opioid agonist, and precursor to vanillactic acid. used for the prevention or alleviation of pain in the eye.

Purity: 98.28% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg Size: 1 mg, 5 mg, 10 mg, 20 mg

[(pF)Phe4]Nociceptin(1-13)NH2 [(pF)Phe4]Nociceptin(1-13)NH2 TFA Cat. No.: HY-P1300 Cat. No.: HY-P1300A

[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent [(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly and selective NOP receptor (OP4) agonist, with a potent and selective NOP receptor (OP4) agonist,

pKi of 10.68 and a pEC50 of 9.31. with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors selectivity over δ, κ, and μ opioid receptors (>3000 fold). (>3000 fold). Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

[Arg14,Lys15]Nociceptin [Arg14,Lys15]Nociceptin TFA Cat. No.: HY-P1301 Cat. No.: HY-P1301A

[Arg14,Lys15]Nociceptin is a highly potent and [Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with selective NOP receptor (ORL1; OP4) agonist, with

an EC50 of 1 nM. [Arg14,Lys15]Nociceptin an EC50 of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, displays high selectivity over opioid receptors,

with IC50s of 0.32, 280, >10000 and 1500 nM for with IC50s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively. NOP, μ, δ and κ receptors, respectively. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

[D-Ala2]leucine-enkephalin [Leu5]-Enkephalin Cat. No.: HY-P0098 (Leu-enkephalin; Leucine enkephalin; Leucyl-enkephalin) Cat. No.: HY-P0288

[D-Ala2]leucine-enkephalin, a delta opioid agonist, [Leu5]-Enkephalin is a pentapeptide with is a degradation resistant long-acting like properties. [Leu5]-Enkephalin is a five amino Leu-enkephalin. acid endogenous peptide that acts as an agonist at opioid receptors.

Purity: 99.77% Purity: 99.81% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 10 mg, 25 mg

[Leu5]-Enkephalin, amide [Met5]-Enkephalin, amide (Leu-Enkephalin amide) Cat. No.: HY-P1470 (5-Methionine-enkephalin amide) Cat. No.: HY-P1467

[Leu5]-Enkephalin, amide is a δ opioid receptor [Met5]-Enkephalin, amide is an agonist for δ agonist. opioid receptors as well as putative ζ ζ opioid receptors.

Purity: 99.44% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mg, 25 mg Size: 1 mg, 5 mg

14 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

[Met5]-Enkephalin, amide TFA [Nphe1]Nociceptin(1-13)NH2 (5-Methionine-enkephalin amide (TFA)) Cat. No.: HY-P1467A Cat. No.: HY-P1320

[Met5]-Enkephalin, amide TFA is an agonist for δ [Nphe1]Nociceptin(1-13)NH2, a novel opioid receptors as well as putative ζ ζ opioid nociceptin/orphanin FQ (NC) endogenous ligand, is receptors. a selective and competitive ociceptin receptor antagonist without any residual agonist activity.

Purity: 99.71% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mg, 25 mg Size: 1 mg, 5 mg

[Nphe1]Nociceptin(1-13)NH2 TFA β-, bovine Cat. No.: HY-P1320A (β-Casomorphin-7 (bovine); Bovine β-casomorphin-7) Cat. No.: HY-P0179

[Nphe1]Nociceptin(1-13)NH2, a novel β-Casomorphin, bovine (β-Casomorphin-7 (bovine) ) nociceptin/orphanin FQ (NC) endogenous ligand, is is a opioid peptide with an IC50 of 14 μM in an a selective and competitive ociceptin receptor Opioid receptors binding assay. antagonist without any residual agonist activity.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 5 mg, 10 mg, 50 mg

β-Casomorphin, bovine TFA (β-Casomorphin-7 (bovine) (TFA); β-Casomorphin, human Bovine β-casomorphin-7 TFA) Cat. No.: HY-P0179A (Human β-casomorphin 7) Cat. No.: HY-P1481

β-Casomorphin, bovine TFA (β-Casomorphin-7 is an opioid peptide, acts as an agonist of opioid

(bovine) TFA) is a opioid peptide with an IC50 of receptor. 14 μM in an Opioid receptors binding assay.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: 5 mg, 10 mg, 50 mg

β-Casomorphin, human TFA β-Endorphin, equine (Human β-casomorphin 7 TFA) Cat. No.: HY-P1481A Cat. No.: HY-P1866

β-Casomorphin, human TFA (Human β-casomorphin 7 β-Endorphin, equine is an endogenous opioid TFA) is an opioid peptide, acts as an agonist of peptide, which binds at high affinity to both μ/δ opioid receptor. opioid receptors. Analgesic properties.

Purity: 99.67% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg Size: 1 mg, 5 mg

β-Endorphin, equine TFA β-Endorphin, human Cat. No.: HY-P1866A Cat. No.: HY-P1502

β-Endorphin, equine (TFA) is an endogenous opioid β-Endorphin, human, a prominent endogenous peptide, which binds at high affinity to both μ/δ peptide, existing in the hypophysis cerebri and opioid receptors. Analgesic properties. hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity. Purity: 97.20% Purity: 97.67% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 500 μg, 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg, 10 mg

www.MedChemExpress.com 15